A BILL 
To hold pharmaceutical companies accountable for dubious 
marketing and distribution of opioid products and for 
their role in creating and exacerbating the opioid epi-
demic in the United States. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Opioid Crisis Account-
4
ability Act of 2019’’. 
5
05:55 Jun 06, 2019
H2917
2 
•HR 2917 IH
SEC. 2. PROHIBITION OF DUBIOUS MARKETING AND MEDI-
1
CALLY UNREASONABLE DISTRIBUTION PRAC-
2
TICES WITH RESPECT TO OPIOIDS. 
3
(a) DUBIOUS MARKETING OR DISTRIBUTION PRAC-
4
TICE WITH RESPECT TO AN OPIOID.— 
5
(1) IN
GENERAL.—In this section, the term 
6
‘‘dubious marketing or distribution practice with re-
7
spect to an opioid’’, subject to paragraph (2), 
8
means— 
9
(A) including in any advertisement, pro-
10
motion, direct-to-consumer marketing materials, 
11
or other marketing material a representation 
12
that an opioid has no addiction-forming or ad-
13
diction-sustaining liability or has less of an ad-
14
diction-forming or addiction-sustaining liability 
15
than 1 or more other opioids, knowing the rep-
16
resentation to be false, as determined by the 
17
Secretary of Health and Human Services (re-
18
ferred to in this section as the ‘‘Secretary’’), in 
19
consultation with the Commissioner of Food 
20
and Drugs (referred to in this section as the 
21
‘‘Commissioner’’), 
based 
on 
research, 
22
testimonials, and other evidence; 
23
(B) knowingly supplying States or commu-
24
nities with a quantity of opioids that the person 
25
knows is not medically reasonable; or 
26
05:55 Jun 06, 2019
H2917
3 
•HR 2917 IH
(C) failing to report to the Secretary any 
1
order or pattern of orders for the distribution 
2
of opioids in a State or community that the per-
3
son knows are not being dispensed in a medi-
4
cally reasonable manner. 
5
(2) LIMITATION.—An act does not constitute a 
6
‘‘dubious marketing or distribution practice with re-
7
spect to an opioid’’, with respect to a natural per-
8
son— 
9
(A) within the meaning of paragraph 
10
(1)(B), if such natural person was not involved 
11
in the decision making regarding the quantity 
12
of opioids to supply; or 
13
(B) within the meaning of paragraph 
14
(1)(C) if such natural person knows that the 
15
Secretary should reasonably be aware of the rel-
16
evant order or pattern of orders for the dis-
17
tribution of opioids. 
18
(b) PROHIBITION.—It shall be unlawful for any per-
19
son involved in the manufacture or distribution of an 
20
opioid to engage in an dubious marketing or distribution 
21
practice with respect to an opioid. 
22
(c) PENALTIES.— 
23
(1) IN
GENERAL.—Any person who violates 
24
subsection (b)— 
25
05:55 Jun 06, 2019
H2917
4 
•HR 2917 IH
(A) if a natural person employed by an 
1
opioid manufacturer or distributor, shall be— 
2
(i) subject to a civil penalty in an 
3
amount equal to the sum of— 
4
(I) such person’s full amount of 
5
salary for each year during which 
6
such person engaged in dubious mar-
7
keting or distribution practices with 
8
respect to an opioid product; and 
9
(II) the amount by which the 
10
stock or other certificates of owner-
11
ship interest of the person that is 
12
owned by the individual has increased 
13
in value during the period during 
14
which such person engaged in dubious 
15
marketing or distribution practices of 
16
an opioid product, without regard to 
17
whether the individual has sold any of 
18
the stock or certificates from such 
19
opioid manufacturer or distributor; 
20
and 
21
(ii) subject to a term of imprison-
22
ment— 
23
(I) with respect to a violation in-
24
volving a drug in schedule II of sec-
25
05:55 Jun 06, 2019
H2917
5 
•HR 2917 IH
tion 202 of the Controlled Substances 
1
Act (21 U.S.C. 812), of not more 
2
than 10 years; or 
3
(II) with respect to a violation in-
4
volving a drug in schedule III of sec-
5
tion 202 of the Controlled Substances 
6
Act (21 U.S.C. 812), of not more 
7
than 5 years; or 
8
(B) if a corporate entity, shall be subject 
9
to a civil penalty in the amount equal to 75 per-
10
cent of the total profit such corporate entity 
11
made on lawful sales of opioids in the United 
12
States during the period in which the corporate 
13
entity engaged in dubious marketing or dis-
14
tribution practices. 
15
(2) OTHER
PENALTIES
APPLICABLE
IN
THE 
16
CASE OF A VIOLATION BY A CORPORATE ENTITY.— 
17
If a person that is a corporate entity violates sub-
18
section (b), the court, without regard to the partici-
19
pation of such individuals in, or knowledge of such 
20
individuals of, the violation, shall— 
21
(A) impose on the chief executive officer 
22
(or equivalent) of the corporate entity a civil 
23
penalty in an amount equal to the sum of— 
24
05:55 Jun 06, 2019
H2917
6 
•HR 2917 IH
(i) the salary of the individual during 
1
the period in which the corporate entity 
2
engaged in dubious marketing or distribu-
3
tion practices and such individual served 
4
as chief executive office; and 
5
(ii) the amount by which the stock or 
6
other certificates of ownership interest of 
7
the corporate entity that is owned by the 
8
individual has increased in value during 
9
the period that the corporate entity en-
10
gaged in dubious marketing or distribution 
11
practices and such individual served as 
12
chief executive officer, without regard to 
13
whether the individual has sold any of the 
14
stock or certificates; 
15
(B) impose on any executive other than the 
16
chief executive officer (or equivalent) who led 
17
the finance, research, marketing, or sales de-
18
partment of the corporate entity a civil penalty 
19
in the amount equal to the sum of— 
20
(i) 25 percent of the salary of the in-
21
dividual during the period that the cor-
22
porate entity engaged in dubious mar-
23
keting or distribution practices and such 
24
individual served as such an executive; and 
25
05:55 Jun 06, 2019
H2917
7 
•HR 2917 IH
(ii) 25 percent of the amount by 
1
which the stock or other certificates of 
2
ownership interest of the corporate entity 
3
that is owned by the individual has in-
4
creased in value during the period that the 
5
corporate entity engaged in dubious mar-
6
keting or distribution practices and such 
7
individual served as such an executive, 
8
without regard to whether the individual 
9
has sold any of the stock or certificates; 
10
and 
11
(C) impose on any executive, including the 
12
chief executive officer (or equivalent) who led 
13
the finance, research, marketing, or sales de-
14
partment of the corporate entity during the cal-
15
endar year in which a court enters a judgment 
16
that the corporate entity violated subsection (b) 
17
and who is not subject to a civil penalty under 
18
subparagraph (A) or (B), a civil penalty in the 
19
amount equal to the sum of— 
20
(i) 25 percent of the salary of the in-
21
dividual from the corporate entity during 
22
the calendar year in which a court enters 
23
such judgment; and 
24
05:55 Jun 06, 2019
H2917
8 
•HR 2917 IH
(ii) 25 percent of the amount by 
1
which the stock or other certificates of 
2
ownership interest of the corporate entity 
3
that is owned by the individual has in-
4
creased in value during the calendar year 
5
in which a court enters such judgment. 
6
(d) RULES FOR APPLICATION.— 
7
(1) QUANTITY OF OPIOIDS COVERED.— 
8
(A) FORMULA.—For purposes of subpara-
9
graphs (B) and (C) of subsection (a)(1), the 
10
Secretary, in consultation with the Attorney 
11
General and, as appropriate, provider groups 
12
and patient advocacy groups, using, if applica-
13
ble, data from the Automated Reports and Con-
14
solidated Ordering System of the Department 
15
of Justice, shall establish a formula for deter-
16
mining the quantity of opioids that is not medi-
17
cally reasonable with respect to a community or 
18
State. 
19
(B) REBUTTABLE
PRESUMPTION.—There 
20
shall be a rebuttable presumption that a person 
21
who supplies a State or community with a 
22
quantity of opioids that is not medically reason-
23
able, as determined using the formula estab-
24
lished under paragraph (1), knowingly supplied 
25
05:55 Jun 06, 2019
H2917
9 
•HR 2917 IH
such 
quantity 
in 
violation 
of 
subsection 
1
(a)(1)(B). 
2
(2) MEDICALLY
REASONABLE
QUANTITIES
IN 
3
AN ORDER.— 
4
(A) GUIDANCE.—For purposes of sub-
5
section (a)(1)(C), the Secretary shall issue 
6
guidance setting forth a procedure that opioid 
7
manufacturers and distributors shall follow to 
8
recognize orders or patterns of orders for the 
9
distribution of opioids that are not medically 
10
reasonable. 
11
(B) REBUTTABLE
PRESUMPTION.—There 
12
shall be a rebuttable presumption that a person 
13
who— 
14
(i) receives an order that the Sec-
15
retary determines to be not medically rea-
16
sonable and does not report such order; 
17
and 
18
(ii) did not follow the procedure set 
19
forth in the guidance described in subpara-
20
graph (A) with respect to such order, 
21
knowingly failed to report as described in sub-
22
section (a)(1)(C). 
23
(e) FEES APPLICABLE TO ALL OPIOID MANUFAC-
24
TURERS AND DISTRIBUTORS.— 
25
05:55 Jun 06, 2019
H2917
10 
•HR 2917 IH
(1) IN GENERAL.—The Secretary shall assess a 
1
fee against each corporate entity that, during the pe-
2
riod beginning on January 1, 1993, and ending on 
3
the day before the date of enactment of this Act, 
4
manufactured or distributed any opioid drug that 
5
was covered by a Federal health program at least 
6
once during such period, in amounts, for each such 
7
manufacturer or distributor, determined by the Sec-
8
retary through rulemaking. 
9
(2) TOTAL AMOUNT.—The Secretary shall en-
10
sure that the total amount assessed under para-
11
graph (1) equals $20,000,000,000. 
12
(3) DUE
DATES.—With respect to a fee as-
13
sessed under this subsection— 
14
(A) not less than 50 percent of the amount 
15
of the fee shall be paid within 1 year of the 
16
date of enactment of this Act; and 
17
(B) 100 percent of such amount shall be 
18
paid not later than 2 years after the date of en-
19
actment of this Act. 
20
(4) WITHDRAWAL OF APPROVAL IN THE CASE 
21
OF NONPAYMENT BY MANUFACTURER.—If a manu-
22
facturer assessed a fee under this subsection fails to 
23
pay the full fee as required under paragraph (3), the 
24
Secretary shall withdraw approval of the application 
25
05:55 Jun 06, 2019
H2917
11 
•HR 2917 IH
under section 505 of the Federal Food, Drug, and 
1
Cosmetic Act (21 U.S.C. 355) for the drug until the 
2
fee is paid in full. 
3
(5) INVESTIGATION.—Immediately after the 
4
date of enactment of this Act, the Secretary, acting 
5
through the Commissioner and in consultation with 
6
the Attorney General, acting through the Adminis-
7
trator of the Drug Enforcement Administration, 
8
shall begin an assessment to set fees under this sub-
9
section. 
10
(f) REIMBURSEMENT OF ECONOMIC IMPACT.— 
11
(1) ESTABLISHMENT OF FUND.—There is es-
12
tablished in the Treasury of the United States a 
13
fund, to be known as the ‘‘Opioids Reimbursement 
14
Fund’’ (referred to in this subsection as the 
15
‘‘Fund’’), to be administered by the Secretary, in 
16
consultation with the Commissioner. 
17
(2) APPROPRIATIONS; 
TRANSFERS
TO
THE 
18
FUND.— 
19
(A) APPROPRIATION.—There is appro-
20
priated, out of any monies in the Treasury not 
21
otherwise appropriated, $20,000,000,000 to the 
22
Fund. 
23
(B) TRANSFERS.—In a manner consistent 
24
with section 3302(b) of title 31, United States 
25
05:55 Jun 06, 2019
H2917
12 
•HR 2917 IH
Code, there shall be transferred to the Fund 
1
from the General Fund of the Treasury an 
2
amount equal to— 
3
(i) the amount of the civil penalties 
4
collected under subsection (c); plus 
5
(ii) the amount of fees collected under 
6
subsection (e). 
7
(C) AVAILABILITY.—Funds appropriated 
8
under paragraph (1) and transferred under 
9
subparagraph (B) shall remain available until 
10
expended. 
11
(3) USE OF FUNDS.— 
12
(A) IN GENERAL.—The Secretary, in con-
13
sultation with the Commissioner, may, without 
14
further appropriation, use amounts in the Fund 
15
to combat the misuse and abuse of opioids in 
16
the United States, which may include transfer-
17
ring amounts from the Fund to other agencies 
18
to carry out programs, projects, and activities 
19
of the agencies to combat the misuse and abuse 
20
of opioids in the United States. 
21
(B) PRIORITY.—In using amounts in the 
22
Fund, the Secretary shall give priority to pro-
23
viding funds for— 
24
05:55 Jun 06, 2019
H2917
13 
•HR 2917 IH
(i) programs, projects, and activities 
1
of the Substance Abuse and Mental Health 
2
Services Administration, the Department 
3
of Labor, the Centers for Disease Control 
4
and Prevention, and the Health Resources 
5
and Services Administration; 
6
(ii) programs, projects, and activities 
7
that provide services to individuals directly 
8
affected by the misuse and abuse of opioids 
9
(including family members of such individ-
10
uals); 
11
(iii) programs, projects, and activities 
12
of the Department of Education related to 
13
national activities for school safety, includ-
14
ing such activities authorized under section 
15
4631 of the Elementary and Secondary 
16
Education Act of 1965 (20 U.S.C. 7281) 
17
to help State and local educational agen-
18
cies implement evidence-based opioid mis-
19
use and abuse prevention strategies for 
20
schools in communities impacted by the 
21
opioid crisis, and particularly for any ap-
22
plicant who describes how such applicant 
23
would use the funds to prevent opioid mis-
24
use and abuse by students and address the 
25
05:55 Jun 06, 2019
H2917
14 
•HR 2917 IH
mental health needs of students affected by 
1
opioid misuse and abuse with their families 
2
or communities; and 
3
(iv) Head Start programs, including 
4
Early Head Start programs, under the 
5
Head Start Act (42 U.S.C. 9831 et seq.) 
6
and the Healthy Start program of the 
7
Health Resources and Services Administra-
8
tion to provide additional qualified child 
9
care providers trained in trauma-informed 
10
care in States with the largest number of 
11
children and families affected by the opioid 
12
crisis in their communities. 
13
(C) AVAILABILITY.—Amounts transferred 
14
to an agency under subparagraph (A) shall re-
15
main available until expended. 
16
(D) 
SUPPLEMENT
NOT
SUPPLANT.— 
17
Amounts transferred to an agency under sub-
18
paragraph (A) to carry out programs, projects, 
19
and activities of the agency shall supplement, 
20
and not supplant, amounts otherwise available 
21
for such purpose. 
22
SEC. 3. REDUCED EXCLUSIVITY. 
23
(a) IN GENERAL.—If a drug manufacturer violates 
24
section 2(b) with respect to a covered opioid, effective on 
25
05:55 Jun 06, 2019
H2917
15 
•HR 2917 IH
the date on which such manufacturer is found to have so 
1
violated such section— 
2
(1) any remaining period of market exclusivity 
3
with respect to such covered opioid shall be revoked; 
4
(2) the period of market exclusivity with respect 
5
to any other opioid for which such manufacturer is 
6
the holder of an approved application under section 
7
505 of the Federal Food, Drug, and Cosmetic Act 
8
(21 U.S.C. 355) or a license under section 351 of 
9
the Public Health Service Act (42 U.S.C. 262) shall 
10
be reduced to one half of the remaining period of 
11
market exclusivity; and 
12
(3) no new or additional exclusivity shall be 
13
awarded to any opioid for which an application is 
14
submitted by such manufacturer for approval under 
15
section 505 of the Federal Food, Drug, and Cos-
16
metic Act (21 U.S.C. 355) or under section 351 of 
17
the Public Health Service Act (42 U.S.C. 262) or 
18
marketed as a result of product hopping. 
19
(b) DEFINITIONS.—For purposes of this section: 
20
(1) COVERED OPIOID.—A ‘‘covered opioid’’ is a 
21
prescription opioid drug, the sales of which in the 
22
United States, beginning on the date on which the 
23
drug was first eligible to be marketed in the United 
24
States and ending on the date on which the manu-
25
05:55 Jun 06, 2019
H2917
16 
•HR 2917 IH
facturer was found to be in violation of section 2(b), 
1
has generated at least $1. 
2
(2) PERIOD
OF
MARKET
EXCLUSIVITY.—The 
3
term ‘‘period of market exclusivity’’ with respect to 
4
a drug means the total period of market exclusivity 
5
granted under clause (ii), (iii), or (iv) of section 
6
505(c)(3)(E) of the Federal Food, Drug, and Cos-
7
metic 
Act 
(21 
U.S.C. 
355(c)(3)(E)), 
section 
8
505(j)(5)(B)(iv) of such Act, clause (ii), (iii), or (iv) 
9
of section 505(j)(5)(F) of such Act, section 527 of 
10
such Act (21 U.S.C. 360cc), or paragraph (6) or (7) 
11
of section 351(k) of the Public Health Service Act 
12
(42 U.S.C. 262(k)), and any extension of such a pe-
13
riod granted under section 505A or 505E of the 
14
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
15
355a, 355f). 
16
(3) PRODUCT
HOPPING.—The term ‘‘product 
17
hopping’’ means a reformulation of an approved 
18
drug or biological product that allows a manufac-
19
turer to submit a new drug application under section 
20
505(b) of the Federal Food, Drug, and Cosmetic Act 
21
(21 U.S.C. 355(b)) or new application for a license 
22
under section 351(a) of the Public Health Service 
23
Act (42 U.S.C. 262(a)) and that— 
24
05:55 Jun 06, 2019
H2917
17 
•HR 2917 IH
(A) is intended for the treatment of the 
1
same medical condition as the drug or biological 
2
product that was originally so approved; and 
3
(B) is undertaken in conjunction with the 
4
sponsor’s actions to reduce or eliminate demand 
5
for the original formulation of the drug or bio-
6
logical product. 
7
Æ 
05:55 Jun 06, 2019
H2917
